Icon Plc

Research Icon Plc (ICLR) on Bullrun: market cap USD 13.03B, P/E 306.6. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 13.03B; P/E is 306.6.

Peer valuation comparison

Latest P/E is 306.61x versus a Healthcare sector median of 24.46x (1153.5% above).

Latest P/E is 306.61x versus a Ireland median of 22.15x (1284.2% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 8.25BUSD 229.34MUSD 861.99M26.1%2.9USD 647.30MUSD 2.87BUSD 9.19B
FY2024USD 8.19BUSD 739.13MUSD 1.12B28.6%8.9USD 538.79MUSD 3.40BUSD 9.44B
FY2023USD 8.05BUSD 554.21MUSD 1.02B29.0%6.7USD 378.10MUSD 3.67BUSD 9.21B
FY2022USD 7.74BUSD 505.30MUSD 421.16M28.6%6.13USD 288.77MUSD 4.60BUSD 8.53B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 13.03B306.6n/an/a
20252025-12-31USD 13.91B24.6n/an/a
20242024-12-31USD 16.94B22.0n/an/a
20232023-12-29USD 23.30B45.6n/an/a
20222022-12-30USD 15.86B34.5n/an/a
20212021-12-31USD 25.26B104.6n/an/a

About Icon Plc

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Icon Plc's market cap?

Icon Plc's market capitalization is USD 13.03B.

What is Icon Plc's P/E ratio?

Icon Plc's price-to-earnings (P/E) ratio is 306.6.

What does Icon Plc do?

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.